Evidence map›Paper›PMID 35690756›Full record

ArticleMalaria journal2022

Incremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation.

Joshua Yukich, Peder Digre, Sara Scates, Luc Boydens, Emmanuel Obi, Nicky Moran, Allison Belemvire, Mariandrea Chamorro, Benjamin Johns, Keziah L Malm and 31 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 11 institutions in 6 countries.

Joshua YukichTropical Health Consulting LLP, London, UK. jyukich@tulane.edu.
Peder DigrePATH, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5109-5386
Sara ScatesTropical Health Consulting LLP, London, UK.
Luc BoydensTropical Health Consulting LLP, London, UK.
Emmanuel ObiTropical Health Consulting LLP, London, UK.
Nicky MoranTropical Health Consulting LLP, London, UK.
Allison BelemvireUS President's Malaria Initiative, US Agency for International Development, Washington, DC, USA.
Mariandrea ChamorroPMI VectorLink Project, Abt Associates, Rockville, MD, USA.
Benjamin JohnsPMI VectorLink Project, Abt Associates, Rockville, MD, USA.
Keziah L MalmNational Malaria Control Programme, Ministry of Health, Accra, Ghana.
Lena KolyadaPMI VectorLink Ghana Project, Abt Associates, Accra, Ghana.
Ignatius WilliamsAngloGold Ashanti Malaria Control Limited, Accra, Ghana.
Samuel AsieduAngloGold Ashanti Malaria Control Limited, Accra, Ghana.
Seydou FombaProgramme National de Lutte Contre le Paludisme, Bamako, Mali.
Jules MihigoUS President's Malaria Initiative, US Agency for International Development, Bamako, Mali.
Desire BokoPMI VectorLink Mali Project, Abt Associates, Bamako, Mali.
Baltazar CandrinhoNational Malaria Control Programme, Ministry of Health, Maputo, Mozambique.
Rodaly MuthoniPMI VectorLink Mozambique, Abt Associates, Maputo, Mozambique.
Jimmy OpigoNational Malaria Control Division, Ministry of Health, Kampala, Uganda.
Catherine Maiteki-SebuguziNational Malaria Control Division, Ministry of Health, Kampala, Uganda.
Damian RutazaanaNational Malaria Control Division, Ministry of Health, Kampala, Uganda.
Josephat ShililuPMI VectorLink Uganda Project, Abt Associates, Kampala, Uganda.
Asaph MuhanguziPMI VectorLink Uganda Project, Abt Associates, Kampala, Uganda.
Kassahun BelayUS President's Malaria Initiative, US Agency for International Development, Kampala, Uganda.
Joel KisubiUS President's Malaria Initiative, US Agency for International Development, Kampala, Uganda.
Joselyn Annet AtuhairweUganda Public Health Fellowship Program, Kampala, Uganda.
Presley MusondaPMI VectorLink Zambia Project, Abt Associates, Lusaka, Zambia.
Nduka IwuchukwuAbt Associates, Lusaka, Zambia.
John NgosaAbt Associates, Lusaka, Zambia.
Elizabeth ChizemaNational Malaria Elimination Centre, Lusaka, Zambia.
Reuben ZuluNational Malaria Elimination Centre, Lusaka, Zambia.
Emmanuel KoomaNational Malaria Elimination Centre, Lusaka, Zambia.
John MillerPATH, Lusaka, Zambia.
Adam BennettMalaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, CA, USA.
Kyra ArnettPATH, Seattle, WA, USA.
Kenzie TynuvPATH, Washington, DC, USA.
Christelle GoguePATH, Washington, DC, USA.
Joseph WagmanPATH, Washington, DC, USA.
Jason H RichardsonIVCC, Washington, DC, USA.
Laurence SlutskerPATH, Seattle, WA, USA.
Molly RobertsonPATH, Washington, DC, USA.
Program for Appropriate Technology in Health · USMinistry of Health · UGNational HIV/AIDS/STI/TB Council · ZMAssociates Research · UGVector (United States) · USCentre Pour le Développement des Vaccins-Mali · MLMinistry of Health · MZMinistry of Health · GHTulane University · USUniversity of California, San Francisco · USU.S. President's Malaria Initiative · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria is a major cause of morbidity and mortality globally, especially in sub-Saharan Africa. Widespread resistance to pyrethroids threatens the gains achieved by vector control. To counter resistance to pyrethroids, third-generation indoor residual spraying (3GIRS) products have been developed. This study details the results of a multi-country cost and cost-effectiveness analysis of indoor residual spraying (IRS) programmes using Actellic

methodsAn economic evaluation of 3GIRS using Actellic

resultsOverall, IRRs from each country indicated that adding IRS with Actellic DISCUSSION: Variations in the incremental costs and cost-effectiveness likely result from several sources including: variation in the sprayed wall surfaces and house size relative to household population, the underlying malaria burden in the communities sprayed, the effectiveness of 3GIRS in different settings, and insecticide price. Programmes should be aware that current recommendations to rotate can mean variation and uncertainty in budgets; programmes should consider this in their insecticide-resistance management strategies.

conclusionsThe optimal combination of 3GIRS delivery with other malaria control interventions will be highly context specific. 3GIRS using Actellic

Indexed as

InsecticidesMalariaOrganothiophosphorus CompoundsPyrethrinsCost-Benefit AnalysisData CollectionHumansMaliMosquito ControlInsecticidesOrganothiophosphorus Compoundspirimiphos methylPyrethrins3GIRSActellic®300CSCostCost-effectivenessIndoor residual sprayingIRSMalariaNgenIRSPirimiphos-methylVector control

Identifiers

PMID35690756
PMCPMC9188086
OpenAlexW4282913306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.